Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy.
Garrido P, Rosell R, Massutí B, Cardenal F, Alberola V, Dómine M, Maeztu I, Ramos A, Arellano A; Spanish Lung Cancer Group 0008 Investigators. Garrido P, et al. Among authors: massuti b. Clin Lung Cancer. 2009 May;10(3):180-6. doi: 10.3816/CLC.2009.n.025. Clin Lung Cancer. 2009. PMID: 19443338 Clinical Trial.
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group. Peters S, et al. Among authors: massuti b. J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23. J Thorac Oncol. 2017. PMID: 28017787 Free article. Clinical Trial.
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. Michels S, et al. Among authors: massuti b. J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9. J Thorac Oncol. 2019. PMID: 30978502 Free article. Clinical Trial.
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation.
Barquín M, Calvo V, García-García F, Nuñez B, Sánchez-Herrero E, Serna-Blasco R, Auglytė M, Carcereny E, Rodriguez-Abreu D, López Castro R, Guirado M, Camps C, Bosch-Barrera J, Massuti B, Ortega AL, Del Barco E, Gonzalez-Larriba JL, Aguiar D, García-Campelo R, Dómine M, Agraso S, Sala MA, Oramas J, Bernabé R, Blanco R, Parejo C, Cruz A, Menasalvas E, Royuela A, Romero A, Provencio M. Barquín M, et al. Among authors: massuti b. Cancer Epidemiol. 2020 Aug;67:101737. doi: 10.1016/j.canep.2020.101737. Epub 2020 May 22. Cancer Epidemiol. 2020. PMID: 32450544
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.
Vicente-Baz D, Paredes A, Morán T, Massuti B, Reguart N, Álvarez R, Insa A, Juan-Vidal O, Artal Á, Esteban E, García-Campelo R, Ortega-Granados AL, Diz P, González-Larriba JL, Terrasa J, de Las Peñas R, Rodríguez-Abreu D, Callejo Á, Márquez G, Provencio M. Vicente-Baz D, et al. Among authors: massuti b. Rev Esp Patol. 2020 Jul-Sep;53(3):140-148. doi: 10.1016/j.patol.2019.11.002. Epub 2020 Jan 13. Rev Esp Patol. 2020. PMID: 32650965
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Provencio M, et al. Among authors: massuti b. Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24. Lancet Oncol. 2020. PMID: 32979984 Clinical Trial.
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
Feliu J, Jorge Fernández M, Macarulla T, Massuti B, Albero A, González González JF, Quintero-Aldana G, Delgado-Mingorance JI, Fernández Montes A, García Piernavieja C, Valladares-Ayerbes M, López Muñoz AM, Mondéjar Solís R, Vicente P, Casado Gonzalez E, González Cebrián I, López-Vivanco G. Feliu J, et al. Among authors: massuti b. Cancer Chemother Pharmacol. 2021 Apr;87(4):543-553. doi: 10.1007/s00280-020-04214-w. Epub 2021 Jan 15. Cancer Chemother Pharmacol. 2021. PMID: 33452559 Clinical Trial.
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, García-Campelo R, Del Barco E, Juan O, Aparisi F, González-Larriba JL, Domine M, Trigo JM, Cobo M, Cerezo S, Calzas J, Massutí B, Bosch-Barrera J, García Coves P, Domènech M, Provencio M. Franco F, et al. Among authors: massuti b. PLoS One. 2021 Jun 2;16(6):e0251761. doi: 10.1371/journal.pone.0251761. eCollection 2021. PLoS One. 2021. PMID: 34077442 Free PMC article.
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Laza-Briviesca R, et al. Among authors: massuti b. Clin Transl Med. 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491. Clin Transl Med. 2021. PMID: 34323406 Free PMC article.
188 results